Loading…
← CockpitCompetitor Analysis › DBV.PA DBV Technologies SAOpen in the cockpit ↗

DBV Technologies SADBV.PACompetitor analysis, valuation and peers

France · EUR·Health Care›Pharmaceuticals: Major
Momentum laggard 4
Mkt cap
$604M
US dollars, full cap
Free float
86%
of shares outstanding
$/day
$2.57M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 6.5%
Hurdle
n/a
no reverse DCF
Next earnings
113 days
11 Mar 2027
Close · EUR€1.75
1D-2.9%
1W-18.0%
1M+2.3%
3M-29.9%
6M-45.7%
YTD-48.2%
1Y-26.8%
ATR %7.2%
52w lowhigh61.1% off high

What DBV Technologies does

Employees: 125

DBV Technologies at a glance

Size DBV Technologies (DBV.PA) is a France Health Care company (Pharmaceuticals: Major) with a market value of $604M, the 163rd largest of 206 France companies the cockpit tracks. Shares closed at €1.75 on 18 Nov 2026.

Performance Over six months the shares fell 45.7%, against -26.6% for the median peer and -2.1% for the France market (cap-weighted) — 4th lowest of 20 in its peer set.

Next results Next results expected around 11 Mar 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 75DBV.PA 54
Six months, rebased to 100: DBV Technologies against the median of its 20 peers (local-currency closes).

DBV Technologies financials

Reported figures in EUR; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue€0€0€0€0€0
Revenue growth—————
Gross profit-€15.3M-€15.6M-€6.31M€4.16M-€20.3M
EBITDA-€167M-€120M-€105M-€89.4M-€76.3M
Net income-€179M-€130M-€105M-€67.3M-€91.6M
Free cash flow-€165M-€108M-€98.7M-€74.3M-€53.7M
Capital expenditure€2.92M€476,706€2.16M€626,205€717,430
Total debt€19.5M€18.5M€14.6M€13.0M€9.39M

Quarterly statements and history in the cockpit →

DBV Technologies competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-60%-40%-20%0%+20%-50%0%+50%300233301096600976185750002793IMMX002940300194ORCHPHARMA4105300147OLMA301211BCAXCGEM2157DBV.PA6-month return →1-month return →
Up and to the right = strong over both horizons. DBV Technologies is the large dot.

DBV Technologies competitors and peer comparison

How DBV Technologies compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

DBV Technologies against its 20 peers (data as of 18 Nov 2026)
MeasureDBV.PAPeer medianRank in peer set
1-month return+2.3%-11.8%3rd highest of 20
6-month return-45.7%-26.6%4th lowest of 20
Distance from 52-week high-61.1%-43.9%6th lowest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
DBV Technologies DBV.PAFrance$604M-46%n/an/an/an/an/a
Shandong Jincheng Pharmaceutical 300233.SZChina$604M-31%+2%4%1.2×-0.6%-1.6%
Hangzhou Bio-Sincerity Pharma-Tech 301096.SZChina$602M-38%+5%-30%7.5×n/an/a
JIANMIN PHARMACEUTICAL 600976.SSChina$598M-14%-2%8%0.9×-6.2%+6.5%
Chongkundang 185750.KSSouth Korea$609M-27%+6%4%0.5×-6.6%+5.4%
Luoxin Pharmaceuticals Group Stock 002793.SZChina$609M-26%-10%-9%2.0×-1.0%-17.9%
Achieve Life Sciences QUITUnited States$609Mn/an/an/an/an/an/a
HeiLongJiang ZBD Pharmaceutical 603567.SSChina$610M-39%-82%n/a25.1×9.1%-25.1%
Immix Biopharma IMMXUnited States$596M-20%n/an/an/an/an/a
Zhejiang Anglikang Pharmaceutical 002940.SZChina$612M-52%-13%10%3.3×10.1%+2.1%
Fuan Pharmaceutical (Group) 300194.SZChina$612M-14%-3%-1%2.4×10.9%-5.9%
Orchid Pharma ORCHPHARMA.NSIndia$613M+30%+11%0%6.1×n/an/a
TTY Biopharm 4105.TWOTaiwan$615M+10%+5%29%3.0×-8.7%+8.8%
Xiangxue Pharmaceutical 300147.SZChina$591M-41%+3%-39%3.7×50.4%-12.3%
Olema Pharmaceuticals OLMAUnited States$619M-49%n/an/an/an/an/a
Hubei Biocause Heilen Pharmaceutical 301211.SZChina$619M-10%+13%4%5.3×n/an/a
Bicara Therapeutics BCAXUnited States$623M-54%n/an/an/an/an/a
Cullinan Therapeutics CGEMUnited States$585M-37%n/an/an/an/an/a
GuiZhou SanLi Pharmaceutical 603439.SSChina$583M-20%-6%5%2.6×20.9%+21.9%
Lepu Biopharma 2157.HKHong Kong$580M-43%+47%7%4.5×n/an/a
Oneness Biotech 4743.TWOTaiwan$580M-13%+19%-589%101.5×n/an/a

Questions

Which companies are DBV Technologies's closest peers?
The cockpit's peer set: Shandong Jincheng Pharmaceutical (300233.SZ), Hangzhou Bio-Sincerity Pharma-Tech (301096.SZ), JIANMIN PHARMACEUTICAL (600976.SS), Chongkundang (185750.KS), Luoxin Pharmaceuticals Group Stock (002793.SZ), Achieve Life Sciences (QUIT), HeiLongJiang ZBD Pharmaceutical (603567.SS), Immix Biopharma (IMMX).
How has DBV Technologies stock performed?
Over six months to 18 Nov 2026 the shares returned -45.7% against -26.6% for the median peer; over one year -26.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.